"The reports said the government is considering decision to half field trials of GM crops. If this is indeed true, we are extremely disappointed by the anti-science, anti-domestic research recommendations which seems motivated to kill the biotechnology sector in India," ABLE-AG, an association of leading biotech companies in India, said in a statement here.
Representatives of Swadeshi Jagran Manch and Bhartiya Kissan Sangh met Environment Minister Prakash Javadekar yesterday, seeking a ban on field trials of genetically-modified crops, cleared by biotech regulator Genetic Engineering Approval Committee (GEAC).
"Seed technologies can control pests and reduce insecticide usage, help farmers manage weeds and also manage their crops from drought, flood, heat, cold, disease or viruses," the statement said.
India's agricultural productivity still ranks far below the best in the world, and if field trials are halted, it will have a far-reaching adverse impact denying new technologies to Indian farmers and the domestic seed industry.
Moreover, India's scientific capabilities will be crippled and domestic investments and innovation by the public and the private sector in agri-biotechnology will cease, it said.
"While taking into account the science and scientific facts, we expect the government to make an informed decision by considering the views of the local industry as well.
"We hope the government will not get swayed by the malicious propaganda against GM technology unleashed by certain groups with vested interests," ABLE AG Chairman Ram Kaundinya said.
ABLE-AG members comprise Indian companies - Advanta, JK, Mahyco, Metahelix, Nath, and also multinational companies -- Bayer, BASF, Devgen, Dow, DuPont Pioneer, Monsanto, Syngenta, Rasi Seeds and Bioseeds.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
